Julian Adams Net Worth

Julian Adams biography

Dr. Julian Adams Ph.D. serves as Chief Executive Officer, Director of the Company. Dr. Adams has more than 35 years of experience in drug discovery and development. From 2003 to 2016, Dr. Adams held roles of increasing responsibility at Infinity Pharmaceuticals, Inc., where he built and led the company’s R&D efforts which ultimately led to the approval of duvelisib, also known as Copiktra®, for the treatment of certain leukemias and lymphomas. Prior to joining Infinity, from 1999 to 2003, Dr. Adams served as a Senior Vice President at Millenium Pharmaceuticals, where he led the development of bortezomib, also known as Velcade®, for the treatment of multiple myeloma. He has served on the boards of directors of numerous biotechnology companies, and currently serves as the Chairman of the board of directors of Elicio Therapeutics. Dr. Adams received a B.S. from McGill University and a Ph.D. from the Massachusetts Institute of Technology in the field of synthetic organic chemistry.

What is the salary of Julian Adams?

As the Chief Executive Officer and Director of Gamida Cell Ltd, the total compensation of Julian Adams at Gamida Cell Ltd is $2,232,000. There are no executives at Gamida Cell Ltd getting paid more.

How old is Julian Adams?

Julian Adams is 65, he's been the Chief Executive Officer and Director of Gamida Cell Ltd since 2017. There are 1 older and 19 younger executives at Gamida Cell Ltd. The oldest executive at Gamida Cell Ltd is Dr. Julian Adams Ph.D., 66, who is the CEO & Director.

What's Julian Adams's mailing address?

Julian's mailing address filed with the SEC is C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE, BOSTON, MA, 02116.

Insiders trading at Gamida Cell Ltd

Over the last 3 years, insiders at Gamida Cell Ltd have traded over $0 worth of Gamida Cell Ltd stock and bought 85,483 units worth $132,499 . The most active insiders traders include Stephen T Wills, Robert I Blum, and Jeremy Blank. On average, Gamida Cell Ltd executives and independent directors trade stock every 0 days with the average trade being worth of $699. The most recent stock trade was executed by Stephen T Wills on 30 September 2022, trading 9,677 units of GMDA stock currently worth $14,999.

What does Gamida Cell Ltd do?

gamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the fda.

Gamida Cell Ltd executives and stock owners

Gamida Cell Ltd executives and other stock owners filed with the SEC include:

• Julian Adams,
  Chief Executive Officer, Director
• Ronit Simantov,
  Chief Medical Officer
• Joshua Hamermesh,
  Chief Business Officer
• Shai Lankry,
  Chief Financial Officer
• Thomas Klima,
  Chief Commercial Officer
• Dr. Julian Adams Ph.D.,
  CEO & Director
• Dr. Ronit Simantov M.D.,
  Chief Medical Officer
• Joshua D. Hamermesh MBA,
  Chief Bus. Officer
• Dr. Jas Uppal,
  Chief Regulatory & Quality Officer
• Shai Lankry CPA, M.B.A.,
  Chief Financial Officer
• Jaren Madden,
  Vice President of Investor Relations and Corporate Communications
• Michael Perry,
  Non-Executive Independent Director
• Kenneth Moch,
  Non-Executive Independent Director
• Ofer Gonen,
  Non-Executive Independent Director
• Nurit Benjamini,
  Non-Executive Independent Director
• stephen Wills,
  Independent Director
• Shawn Tomasello,
  Independent Director
• David Fox,
  Independent Director
• Jas Uppal,
  Chief Regulatory and Quality Officer
• Tracey Lodie,
  Chief Scientific Officer
• Tzvi Palash,
  Chief Operating Officer
• Robert Blum,
  Non-Executive Independent Chairman of the Board
• Joshua F. Patterson,
  Gen. Counsel
• Naftali Brikashvili CPA,
  Sr. VP Fin. & Operations
• Matthew Metivier,
  VP of Human Resource
• Paul Nee,
  VP of Marketing
• Michele Ilene Korfin M.B.A., R.Ph.,
  Chief Operating & Chief Commercial Officer
• Jeremy Blank,
  Director
• Naama Halevi Davidov,
  Director
• Anat Cohen Dayag,
  Director
• Michele Ilene Korfin,
  COO/CHIEF COMMERCIAL OFFICER
• Ivan M. Borrello,
  
• Abigail L. Jenkins,
  President and CEO
• Joshua F. Patterson,
  GENERAL COUNSEL
• Mary Theresa Coelho,
  Chief Financial Officer